Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 3/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.67 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.67 |
| ▸ | FECH | P22830 | 1/20 | 0.67 |
| ▸ | JAK1 | P23458 | 1/20 | 0.67 |
| ▸ | TYK2 | P29597 | 1/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.67 |
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373329 | 0.97 | CLK2 (0.68) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL4606071 | 0.94 | GAK (0.59) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL5372572 | 0.88 | MAPK8 (0.62) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL5380287 | 0.87 | MAPK8 (0.71) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL5375708 | 0.81 | GAK (0.62) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL5373334 | 0.81 | CLK2 (0.98) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL5373389 | 0.81 | CHEK2 (0.56) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL7532858 | 0.80 | MAPK8 (0.71) | CLK2DYRK1AGAKDYRK3JAK2 | |
| SCHEMBL5380905 | 0.80 | MAPK8 (0.71) | CLK2DYRK1AGAKDYRK3JAK2 | |
| Cc-401 SCHEMBL30290855 | 0.80 | CLK2 (1.00) | CLK2DYRK1AGAKDYRK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106702-A2 | TREATMENT OF LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-09 | — | — | WO | claimed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-20140206624-A1 | TREATMENT OF LEUKEMIA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012106702-A2 | TREATMENT OF LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-09 | — | — | WO | disclosed |
| EP-1684690-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| CN-101208333-A | Solid forms of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene | CELGENE CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-101208333-A | Solid forms of 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene | CELGENE CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1891051-A2 | SOLID FORMS OF 1-( 5-(IH-I , 2 , 4 -TRIAZOL- 5 -YL)(1H-INDAZOL-3-YL))-3-(2-PIPERIDYLETHOXY)BENZENE | CELGENE CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1891051-A2 | SOLID FORMS OF 1-( 5-(IH-I , 2 , 4 -TRIAZOL- 5 -YL)(1H-INDAZOL-3-YL))-3-(2-PIPERIDYLETHOXY)BENZENE | CELGENE CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1871364-A1 | METHODS FOR TREATING OR PREVENTING ACUTE MYELOGENOUS LEUKEMIA | Signal Pharmaceuticals LLC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| WO-2004041191-A2 | METHODS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092568-A1 | Methods for the treatment, prevention and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CLK2 352/4885DYRK1A 1188/4885GAK 851/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CLK2 322/4885DYRK1A 784/4885GAK 246/4885 |
| US-20040092568-A1 | Methods for the treatment, prevention and management of macular degeneration | ALDH1A2, MAPK1, MAPK3 | CLK2 634/4885DYRK1A 1988/4885GAK 359/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CLK2 322/4885DYRK1A 784/4885GAK 246/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CLK2 398/4885DYRK1A 426/4885GAK 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.